New Delhi: India is currently under a second wave of corona virus, as well as vaccination. Experts have indicated that if the third wave of corona occurs, it could have a dangerous effect on children as well. In the same order, a big step has now been taken. The Subject Expert Committee (SEC) on Corona Vaccine on Tuesday recommended the trial of Bharat Biotech's covaxin on children between the ages of 2 and 18, which has been flagged off.
The clinical trial will be conducted on 525 people in MIMS hospitals at Delhi AIIMS, Patna AIIMS, Nagpur. According to the recommendations of the committee, Bharat Biotech will have to provide complete second phase data before starting the third phase of trial. SEC had recommended that India should approve the clinical trial of Phase 2, Phase 3 of The Covaccine of Bayatech, which will be conducted on children from 2 to 18 years of age.
Let us tell you that two vaccines currently being used in India are being vaccinated only for people above the age of 18 years. People in India are being given the dose of covishield of Serum Institute, Covaxin of Bharat Biotech.
Sonia Gandhi form five-member team to review humiliating defeat in elections
China's economic recovery: UN report forecasts stronger world economic growth
